{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,24]],"date-time":"2026-07-24T10:43:19Z","timestamp":1784889799249,"version":"3.55.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14992-2","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:04:33Z","timestamp":1761041073000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Impact of biliary drainage for unresectable pancreatic cancer treated with nanoliposomal irinotecan with fluorouracil and folinic acid: retrospective results from the NAPOLEON-2 study"],"prefix":"10.1186","volume":"25","author":[{"given":"Kazuo","family":"Nishikawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Otsuka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mototsugu","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Inagaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azusa","family":"Komori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akiko","family":"Todaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Otsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taro","family":"Shibuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junichi","family":"Nakazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiho","family":"Arima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Miwa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Futa","family":"Koga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yujiro","family":"Ueda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshihito","family":"Kubotsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hozumi","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shigeyuki","family":"Takeshita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayumu","family":"Hosokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsunori","family":"Sakai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hisanobu","family":"Oda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Machiko","family":"Kawahira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuji","family":"Arita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Honda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroki","family":"Taguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kengo","family":"Tsuneyoshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiro","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takahiro","family":"Sakae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasunori","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsuyoshi","family":"Shirakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshihiko","family":"Mizuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenji","family":"Mitsugi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"14992_CR1","doi-asserted-by":"publisher","first-page":"4698","DOI":"10.3748\/wjg.v28.i32.4698","volume":"28","author":"I Ilic","year":"2022","unstructured":"Ilic I, Ilic M. International patterns in incidence and mortality trends of pancreatic cancer in the last three decades: a joinpoint regression analysis. World J Gastroenterol. 2022;28:4698\u2013715.","journal-title":"World J Gastroenterol"},{"key":"14992_CR2","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1053\/j.gastro.2023.02.012","volume":"164","author":"EM Stoffel","year":"2023","unstructured":"Stoffel EM, Brand RE, Goggins M. Pancreatic cancer: changing epidemiology and new approaches to risk assessment, early detection, and prevention. Gastroenterology. 2023;164:752\u201365.","journal-title":"Gastroenterology"},{"key":"14992_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics11030562","volume":"11","author":"J Ushio","year":"2021","unstructured":"Ushio J, Kanno A, Ikeda E, Ando K, Nagai H, Miwata T, et al. Pancreatic ductal adenocarcinoma: epidemiology and risk factors. Diagnostics. 2021;11:562.","journal-title":"Diagnostics"},{"key":"14992_CR4","unstructured":"Cancer Registry and Statistics Cancer Information Service, National Cancer Center. Japan (Ministry of Health, Labour and Welfare, National Cancer Registry). https:\/\/ganjoho.jp\/reg_stat\/statistics\/stat\/summary.html. Accessed 1 Feb 2024."},{"key":"14992_CR5","doi-asserted-by":"publisher","first-page":"3157","DOI":"10.3748\/wjg.v21.i11.3157","volume":"21","author":"D Ansari","year":"2015","unstructured":"Ansari D, Gustafsson A, Andersson R. Update on the management of pancreatic cancer: surgery is not enough. World J Gastroenterol. 2015;21:3157\u201365.","journal-title":"World J Gastroenterol"},{"key":"14992_CR6","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","volume":"369","author":"DD Von Hoff","year":"2013","unstructured":"Von Hoff DD, Ervin T, Arena FP, Chiorean EG, Infante J, Moore M, et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine. N Engl J Med. 2013;369:1691\u2013703.","journal-title":"N Engl J Med"},{"key":"14992_CR7","doi-asserted-by":"publisher","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","volume":"364","author":"T Conroy","year":"2011","unstructured":"Conroy T, Desseigne F, Ychou M, Bouch\u00e9 O, Guimbaud R, B\u00e9couarn Y, et al. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer. N Engl J Med. 2011;364:1817\u201325.","journal-title":"N Engl J Med"},{"key":"14992_CR8","doi-asserted-by":"publisher","first-page":"S894","DOI":"10.1016\/j.annonc.2023.09.2565","volume":"34","author":"A Ohba","year":"2023","unstructured":"Ohba A, Ozaka M, Ogawa G, Okusaka T, Kobayashi S, Yamashita T, et al. 1616O Nab-paclitaxel plus gemcitabine versus modified folfirinox or S-IROX in metastatic or recurrent pancreatic cancer (JCOG1611, GENERATE): A multicentred, randomized, open-label, three-arm, phase II\/III trial. Ann Oncol. 2023;34:S894.","journal-title":"Ann Oncol"},{"key":"14992_CR9","doi-asserted-by":"publisher","first-page":"545","DOI":"10.1016\/S0140-6736(15)00986-1","volume":"387","author":"A Wang-Gillam","year":"2016","unstructured":"Wang-Gillam A, Li CP, Bodoky G, Dean A, Shan YS, Jameson G, et al. Nanoliposomal irinotecan with fluorouracil and folinic acid in metastatic pancreatic cancer after previous gemcitabine-based therapy (NAPOLI-1): a global, randomised, open-label, phase 3 trial. Lancet. 2016;387:545\u201357.","journal-title":"Lancet"},{"key":"14992_CR10","doi-asserted-by":"publisher","first-page":"9396","DOI":"10.1002\/cam4.3558","volume":"9","author":"M Ueno","year":"2020","unstructured":"Ueno M, Nakamori S, Sugimori K, Kanai M, Ikeda M, Ozaka M, et al. Nal-IRI+5-FU\/LV versus 5-FU\/LV in post-gemcitabine metastatic pancreatic cancer: randomized phase 2 trial in Japanese patients. Cancer Med. 2020;9:9396\u2013408.","journal-title":"Cancer Med"},{"key":"14992_CR11","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1097\/MPA.0b013e3181e21b1b","volume":"39","author":"A Weber","year":"2010","unstructured":"Weber A, Kehl V, Mittermeyer T, Herberich E, R\u00f6thling N, Schmid RM, et al. Prognostic factors for survival in patients with unresectable pancreatic cancer. Pancreas. 2010;39:1247\u201353.","journal-title":"Pancreas"},{"key":"14992_CR12","doi-asserted-by":"publisher","first-page":"12422","DOI":"10.1038\/s41598-024-63172-y","volume":"14","author":"T Kodama","year":"2024","unstructured":"Kodama T, Imajima T, Shimokawa M, Otsuka T, Kawahira M, Nakazawa J, et al. A multicenter retrospective observational NAPOLEON2 study of nanoliposomal irinotecan with fluorouracil and folinic acid in patients with unresectable pancreatic cancer. Sci Rep. 2024;14:12422.","journal-title":"Sci Rep"},{"key":"14992_CR13","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.ejca.2016.03.082","volume":"62","author":"LH Schwartz","year":"2016","unstructured":"Schwartz LH, Seymour L, Liti\u00e8re S, Ford R, Gwyther S, Mandrekar S, et al. RECIST 1.1\u2014standardisation and disease-specific adaptations: perspectives from the RECIST working group. Eur J Cancer. 2016;62:138\u201345.","journal-title":"Eur J Cancer"},{"key":"14992_CR14","unstructured":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5. Published: November 27. United States Department of Health and Human Services, National Institutes of Health \u2013 National Cancer Institute; 2017."},{"issue":"5","key":"14992_CR15","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1007\/s10147-021-01859-2","volume":"26","author":"T Otsuka","year":"2021","unstructured":"Otsuka T, Shirakawa T, Shimokawa M, Koga F, Kawaguchi Y, Ueda Y, et al. A multicenter propensity score analysis of FOLFIRINOX vs gemcitabine plus nab-paclitaxel administered to patients with metastatic pancreatic cancer: results from the NAPOLEON study. Int J Clin Oncol. 2021;26(5):941\u201350.","journal-title":"Int J Clin Oncol"},{"key":"14992_CR16","doi-asserted-by":"publisher","first-page":"175883591985319","DOI":"10.1177\/1758835919853196","volume":"11","author":"M Kieler","year":"2019","unstructured":"Kieler M, Unseld M, Bianconi D, Scheithauer W, Prager GW. A real-world analysis of second-line treatment options in pancreatic cancer: Liposomal-irinotecan plus 5-fluorouracil and folinic acid. Ther Adv Med Oncol. 2019;11:1758835919853196.","journal-title":"Ther Adv Med Oncol"},{"key":"14992_CR17","doi-asserted-by":"publisher","first-page":"7420","DOI":"10.1038\/s41598-020-64421-6","volume":"10","author":"YY Su","year":"2020","unstructured":"Su YY, Chiang NJ, Tsai HJ, Yen CJ, Shan YS, Chen LT. The impact of liposomal irinotecan on the treatment of advanced pancreatic adenocarcinoma: real-world experience in a Taiwanese cohort. Sci Rep. 2020;10:7420.","journal-title":"Sci Rep"},{"key":"14992_CR18","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1186\/s12885-018-4605-1","volume":"18","author":"DC Glassman","year":"2018","unstructured":"Glassman DC, Palmaira RL, Covington CM, Desai AM, Ku GY, Li J, et al. Nanoliposomal irinotecan with fluorouracil for the treatment of advanced pancreatic cancer, a single institution experience. BMC Cancer. 2018;18:693.","journal-title":"BMC Cancer"},{"key":"14992_CR19","doi-asserted-by":"publisher","first-page":"175883591987112","DOI":"10.1177\/1758835919871126","volume":"11","author":"C Yoo","year":"2019","unstructured":"Yoo C, Im HS, Kim KP, Oh DY, Lee KH, Chon HJ, et al. Real-world efficacy and safety of liposomal irinotecan plus fluorouracil\/leucovorin in patients with metastatic pancreatic adenocarcinoma: a study by the Korean Cancer Study Group. Ther Adv Med Oncol. 2019;11:1758835919871126.","journal-title":"Ther Adv Med Oncol"},{"key":"14992_CR20","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1186\/s12885-021-08887-1","volume":"21","author":"SJ Park","year":"2021","unstructured":"Park SJ, Kim H, Shin K, Hong TH, Suh JH, Lee MA. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study. BMC Cancer. 2021;21:1176.","journal-title":"BMC Cancer"},{"key":"14992_CR21","doi-asserted-by":"publisher","first-page":"175883592211195","DOI":"10.1177\/17588359221119539","volume":"14","author":"JW Chun","year":"2022","unstructured":"Chun JW, Woo SM, Lee SH, Choi JH, Park N, Kim JS, et al. A real-world analysis of nanoliposomal-irinotecan with 5-fluorouracil and folinic acid as third- or later-line therapy in patients with metastatic pancreatic adenocarcinoma. Ther Adv Med Oncol. 2022;14:17588359221119540.","journal-title":"Ther Adv Med Oncol"},{"key":"14992_CR22","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/j.pan.2022.06.004","volume":"22","author":"S Tezuka","year":"2022","unstructured":"Tezuka S, Ueno M, Kobayashi S, Hamaguchi T, Yamachika Y, Oishi R, et al. Nal-IRI\/5-FU\/LV versus modified FOLFIRINOX and FOLFIRI as second-line chemotherapy for unresectable pancreatic cancer: a single center retrospective study. Pancreatology. 2022;22:789\u201396.","journal-title":"Pancreatology"},{"key":"14992_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.04.461","volume":"31","author":"T Honda","year":"2020","unstructured":"Honda T, Takayuki O, Shimokawa M, Koga F, Ueda Y, Nakazawa J, et al. PD-5 impact of biliary drainage for unresectable pancreatic cancer treated with folfirinox or gemcitabine plus nab-paclitaxel: results from the Napoleon study. Ann Oncol. 2020;31:S213.","journal-title":"Ann Oncol"},{"key":"14992_CR24","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1093\/jjco\/hyy132","volume":"48","author":"T Terashima","year":"2018","unstructured":"Terashima T, Yamashita T, Sakai A, Ohta H, Hinoue Y, Toya D, et al. Treatment patterns and outcomes of unresectable pancreatic cancer patients in real-life practice: a region-wide analysis. Jpn J Clin Oncol. 2018;48:966\u201373.","journal-title":"Jpn J Clin Oncol"},{"key":"14992_CR25","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1056\/NEJM199511023331802","volume":"333","author":"PJ Bosma","year":"1995","unstructured":"Bosma PJ, Chowdhury JR, Bakker C, Gantla S, de Boer A, Oostra BA, et al. The genetic basis of the reduced expression of bilirubin UDP-glucuronosyltransferase 1 in Gilbert\u2019s syndrome. N Engl J Med. 1995;333:1171\u20135.","journal-title":"N Engl J Med"},{"key":"14992_CR26","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0272918","volume":"17","author":"N Pausawasdi","year":"2022","unstructured":"Pausawasdi N, Termsinsuk P, Charatcharoenwitthaya P, Limsrivilai J, Kaosombatwattana U. Development and validation of a risk score for predicting clinical success after endobiliary stenting for malignant biliary obstruction. PLoS ONE. 2022;17:e0272918.","journal-title":"PLoS ONE"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14992-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14992-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T22:02:04Z","timestamp":1761084124000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14992-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":26,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14992"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14992-2","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6755345\/v1","asserted-by":"object"}]},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"27 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with the ethical standards of the responsible committees for clinical study (institutional and national) and the Declaration of Helsinki of 1964 and its later versions and was centrally approved by the Institutional Review Board of Sasebo Kyosai Hospital (study ID 2021\u201308), and also approved by the Institutional Review Boards or Ethics Committee of the following institutions: Kagoshima City Hospital, National Cancer Center Hospital East, Kagoshima University Hospital, Kurume University Hospital, Saga Medical Center Koseikan, Japanese Red Cross Kumamoto Hospital, Karatsu Red Cross Hospital, Japan Community Healthcare Organization Kyushu Hospital, Japanese Red Cross Nagasaki Genbaku Hospital, Oita University Hospital, University of Miyazaki Hospital, National Hospital Organization Kumamoto Medical Center, Saiseikai Kumamoto Hospital, Kagoshima Kouseiren Hospital, Miyazaki Prefectural Miyazaki Hospital, Nagasaki University Hospital, Izumi General Medical Center, Asakura Medical Association Hospital, and Saiseikai Sendai Hospital prior to the study. Because this study was a retrospective observational study conducted in Japan, informed consent was obtained using the opt-in\/opt-out approach according to each participating institution\u2019s policy. Clinical trial number: not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtained using the opt-in\/opt-out approach according to each participating institution\u2019s policy.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1614"}}